Literature DB >> 16503142

Design of a potent, soluble glucokinase activator with excellent in vivo efficacy.

Darren McKerrecher1, Joanne V Allen, Peter W R Caulkett, Craig S Donald, Mark L Fenwick, Emma Grange, Keith M Johnson, Craig Johnstone, Clifford D Jones, Kurt G Pike, John W Rayner, Rolf P Walker.   

Abstract

The optimisation of a series of glucokinase activators is described, including attempts to uncouple the relationship between potency and plasma protein binding, and to better understand the key pharmacokinetic properties of the series. The use of unbound clearance as an optimisation parameter facilitated the identification of GKA50, a compound which combines excellent potency and pharmacokinetics with good free drug levels and solubility, and exhibits in vivo efficacy at 1mg/kg po in an acute rat OGTT model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16503142     DOI: 10.1016/j.bmcl.2006.02.022

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  14 in total

Review 1.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Authors:  Dennis A Smith; Li Di; Edward H Kerns
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

2.  S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice.

Authors:  Frédéric De Ceuninck; Catherine Kargar; Yves Charton; Solo Goldstein; Françoise Perron-Sierra; Catherine Ilic; Audrey Caliez; Jean-Olivier Rolin; Marjorie Sadlo; Elizabeth Harley; Cédric Vinson; Alain Ktorza
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

3.  The use of docking-based comparative intermolecular contacts analysis to identify optimal docking conditions within glucokinase and to discover of new GK activators.

Authors:  Mutasem O Taha; Maha Habash; Mohammad A Khanfar
Journal:  J Comput Aided Mol Des       Date:  2014-03-08       Impact factor: 3.686

4.  Identification of RO4597014, a Glucokinase Activator Studied in the Clinic for the Treatment of Type 2 Diabetes.

Authors:  Yimin Qian; Wendy L Corbett; Steven J Berthel; Duk Soon Choi; Mark T Dvorozniak; Wanping Geng; Paul Gillespie; Kevin R Guertin; Nancy-Ellen Haynes; Robert F Kester; Francis A Mennona; David Moore; Jagdish Racha; Roumen Radinov; Ramakanth Sarabu; Nathan R Scott; Joseph Grimsby; Navita L Mallalieu
Journal:  ACS Med Chem Lett       Date:  2013-03-07       Impact factor: 4.345

5.  Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats.

Authors:  G J Coope; A M Atkinson; C Allott; D McKerrecher; C Johnstone; K G Pike; P C Holme; H Vertigan; D Gill; M P Coghlan; B Leighton
Journal:  Br J Pharmacol       Date:  2006-08-21       Impact factor: 8.739

6.  Discovery of a novel site regulating glucokinase activity following characterization of a new mutation causing hyperinsulinemic hypoglycemia in humans.

Authors:  Nicola L Beer; Martijn van de Bunt; Kevin Colclough; Christine Lukacs; Paul Arundel; Constance L Chik; Joseph Grimsby; Sian Ellard; Anna L Gloyn
Journal:  J Biol Chem       Date:  2011-03-29       Impact factor: 5.157

7.  Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.

Authors:  D J Baker; G P Wilkinson; A M Atkinson; H B Jones; M Coghlan; A D Charles; B Leighton
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

8.  Effects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 beta cells.

Authors:  P Wei; M Shi; S Barnum; H Cho; T Carlson; J D Fraser
Journal:  Diabetologia       Date:  2009-07-30       Impact factor: 10.122

9.  Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans.

Authors:  Frédéric De Ceuninck; Catherine Kargar; Catherine Ilic; Audrey Caliez; Jean-Olivier Rolin; Thierry Umbdenstock; Cédric Vinson; Murielle Combettes; Brant de Fanti; Elizabeth Harley; Marjorie Sadlo; Anne-Laure Lefèvre; Olivier Broux; Michel Wierzbicki; Jean-Marie Fourquez; Françoise Perron-Sierra; András Kotschy; Alain Ktorza
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

10.  Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions.

Authors:  M C T Fyfe; J R White; A Taylor; R Chatfield; E Wargent; R L Printz; T Sulpice; J G McCormack; M J Procter; C Reynet; P S Widdowson; P Wong-Kai-In
Journal:  Diabetologia       Date:  2007-04-06       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.